Amphastar Pharmaceuticals IncAMPH
Price$25.81Intrinsic value$28.4910% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $28.49median of 6 methods · middle span $25-$45based on filings through 30 Jun 2026
Market Price $25.81Price as of 30 Sep 2026
Margin of Safety +10.4%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: -13.9% (near-term consensus, capped) · years 2–5: 5.5%/yr (balance of the path).1.3% per year
Years 6–10: glide to demonstrated growth own history 72.6%, capped at 20%
Per-year rates
Yr 65.0%Yr 74.5%Yr 84.0%Yr 93.5%Yr 103.0%
5.5% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/6y) (limited history)72.6%
Discount rate (cost of equity) 9.2%
Volatility vs market (adjusted beta)0.95

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetAmphastar Pharmaceuticals IncAMPHHealth Care
Valuation
P/E15.3×
P/S1.4×
P/B1.4×
EV / Revenue1.9×
EV / EBITDA6.6×
Profitability
Gross margin41.1%
Operating margin7.9%
Net margin10.8%
FCF margin20.9%
Returns
ROE10.2%
ROA4.5%
ROIC6.7%
Growth
Revenue growth (YoY)-0.3%
5-yr fwd EPS growth1.3%
Financial strength
Debt / Equity0.81×
Current ratio2.40×
Altman Z-Score2.1
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.